NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics has announced that it has received expanded MolDX coverage for its RaDaR® ST MRD assay, which is used for monitoring treatment responses to immunotherapy in late-stage solid tumors.
FORT MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.